Overview

A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.

Phase:

PHASE1

Details

Lead Sponsor:

China Medical University, China

Collaborator:

Immvira Co., Limited

Treatments:

regorafenib
toripalimab